How to Help Your Patients Find Besremi in Stock: A Provider's Guide

How to Help Your Patients Find Besremi in Stock: A Provider's Guide

Your polycythemia vera patients depend on consistent access to Besremi (Ropeginterferon Alfa-2b-njft) to manage their disease. When supply pressure creates access gaps, the burden often falls on your practice to troubleshoot. This guide provides a practical, actionable framework for helping your patients get Besremi — and what to do when they can't.

Current Availability Landscape

Besremi is not in a formal FDA drug shortage, but real-world access has become more challenging since the Pegasys (Peginterferon Alfa-2a) shortage began in 2024. Key factors affecting your patients' ability to fill prescriptions:

• Demand surge: NCCN guideline updates in January 2025 recommending Besremi as a substitute for Pegasys have driven a significant increase in new prescriptions
• Specialty-only distribution: Besremi is exclusively available through specialty pharmacies — not retail chains
• Prior authorization requirements: Nearly all payers require PA, with processing times of 3-7 business days
• Step therapy barriers: Some plans mandate documented Hydroxyurea failure before authorizing Besremi

For a detailed timeline of how the interferon shortage developed, see our provider briefing on Besremi shortage: what prescribers need to know.

Why Patients Can't Find Besremi

When patients report they "can't find" Besremi, the root cause usually falls into one of these categories:

1. Specialty pharmacy stock-out: Their assigned pharmacy doesn't have inventory. This is the most common and most solvable issue.
2. Prior authorization delay: Insurance hasn't approved the prescription yet, and the pharmacy is holding it.
3. Insurance denial: The plan denied coverage, and the patient believes the drug is unavailable (when it's really a coverage issue).
4. Cost barrier: The patient received a cost estimate they can't afford and stopped pursuing the prescription.
5. Patient confusion: The patient checked retail pharmacies instead of understanding the specialty pharmacy pathway.

Identifying the actual barrier quickly is essential to resolving it efficiently.

What Providers Can Do: 5 Steps

Step 1: Verify the Real Barrier

Before investing time in solutions, have your team quickly determine whether the issue is supply, insurance, cost, or patient education. A brief phone call to the specialty pharmacy can usually clarify the situation in minutes.

Step 2: Check Availability on Medfinder

Medfinder for Providers lets your staff search specialty pharmacies for real-time Besremi availability. This is especially useful when your patient's primary specialty pharmacy is out of stock and you need to identify alternatives quickly.

Integrate Medfinder into your standard workflow for any specialty medication access issue — it works for other hard-to-find drugs beyond Besremi.

Step 3: Proactively Manage Prior Authorization

Prior authorization is the single biggest controllable delay in the Besremi access process. To minimize delays:

• Submit PA with the initial prescription — don't wait for the pharmacy to trigger it
• Include clinical documentation upfront: Diagnosis (ICD-10: D45 for PV), JAK2 mutation status, prior treatments tried, and rationale for Besremi
• Use PharmaEssentia SOURCE PA support: Their team can assist with PA submissions and appeals. Provider line: 1-833-546-7473
• Have a template PA letter ready for Besremi — you'll use it frequently

Step 4: Enroll Patients in Financial Assistance Before They Need It

Don't wait for patients to report cost as a barrier. At the time of prescribing:

• Enroll commercially insured patients in the PharmaEssentia Copay Assistance Program at BESREMiCopay.com (eligible patients pay as little as $0/month)
• For uninsured or underinsured patients, initiate the Patient Assistance Program (PAP) through PharmaEssentia SOURCE
• For Medicare patients, explore foundation-based copay assistance programs

Proactive enrollment prevents cost surprises that lead to treatment abandonment. For detailed financial guidance, see our provider's guide to helping patients save money on Besremi.

Step 5: Maintain Communication With the Specialty Pharmacy

Establish a relationship with your specialty pharmacy reps. Regular communication helps you:

• Get advance notice of supply constraints
• Fast-track urgent refills for patients at risk of treatment interruption
• Coordinate smooth transfers between specialty pharmacies when needed

Alternatives When Besremi Is Unavailable

When Besremi cannot be obtained in a clinically acceptable timeframe, these alternatives should be considered:

Hydroxyurea (Hydrea, Droxia)

• Standard first-line cytoreductive therapy for PV
• Oral, daily dosing — widely available and inexpensive ($30-$100/month generic)
• Does not reduce JAK2 mutant clone burden
• Useful as a bridge therapy during Besremi access gaps

Ruxolitinib (Jakafi)

• FDA-approved for PV patients with inadequate response to or intolerance of Hydroxyurea
• Oral, twice-daily dosing
• Effective for symptom control (pruritus, fatigue, splenomegaly)
• High cost (~$15,000-$18,000/month without insurance)

Increased Phlebotomy

• Can serve as a temporary bridge during treatment transitions
• Target hematocrit <45%
• Does not address leukocytosis, thrombocytosis, or symptom burden

For a patient-facing version of this information, direct patients to our article on alternatives to Besremi.

Workflow Tips for Your Practice

Create a Besremi Access Checklist

Develop a standardized workflow for your staff to follow each time Besremi is prescribed or refilled:

1. Confirm patient eligibility (no contraindications per Boxed Warning)
2. Submit prescription to specialty pharmacy
3. Initiate prior authorization with clinical documentation
4. Enroll patient in copay or PAP program
5. Set a follow-up date to confirm pharmacy received approval
6. Confirm delivery with patient before the scheduled dose date

Designate a Specialty Pharmacy Liaison

Having one staff member responsible for specialty pharmacy coordination can dramatically improve turnaround times. This person should:

• Have direct contact information for specialty pharmacy reps
• Track all pending Besremi prescriptions and PA statuses
• Escalate supply issues to PharmaEssentia SOURCE promptly

Educate Patients at First Prescribing

Many access delays stem from patient confusion about the specialty pharmacy process. At the time of prescribing, ensure patients understand:

• Besremi is not available at retail pharmacies
• It will be shipped to their home and must be refrigerated
• The first fill may take 1-3 weeks
• They should request refills 7-10 days early
• Financial assistance is available and should be set up before the first bill arrives

Final Thoughts

Besremi access requires a proactive, systems-based approach. The providers who report the fewest patient access issues are the ones who have standardized their PA workflows, built relationships with specialty pharmacy reps, and enrolled patients in financial assistance programs before problems arise.

Use Medfinder for Providers as a real-time availability tool, leverage PharmaEssentia SOURCE for pharmacy coordination and PA support, and keep your patients informed throughout the process. Consistent communication and early intervention are the keys to keeping your PV patients on therapy.